Edwards Lifesciences (EW) Cash & Equivalents (2009 - 2026)

Edwards Lifesciences has reported Cash & Equivalents for 18 years, with the latest figure at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 22.13% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (down 22.13% YoY), and the FY2025 full-year result was $2.9 billion, down 3.52% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.4 billion, down from $2.9 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.7 billion in Q3 2024, with the low at $761.5 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $1.9 billion, with a median of $1.4 billion recorded in 2023.
• Year-over-year, Cash & Equivalents surged 168.94% in 2024 and dropped 26.95% in 2025.
• Tracing EW's Cash & Equivalents over 5 years: stood at $761.5 million in 2022, then jumped by 48.69% to $1.1 billion in 2023, then soared by 168.94% to $3.0 billion in 2024, then slipped by 3.52% to $2.9 billion in 2025, then declined by 16.76% to $2.4 billion in 2026.
• The last three Cash & Equivalents figures came in at $2.4 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.

Peer Comparison